Patents by Inventor Barton F. Haynes

Barton F. Haynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thymic atrophy
    Publication number: 20040131619
    Abstract: The present invention relates, in general, to thymic atrophy and, in particular, to a method of treating or preventing thymic atrophy in septic shock.
    Type: Application
    Filed: September 30, 2003
    Publication date: July 8, 2004
    Applicant: DUKE UNIVERSITY
    Inventors: Gregory D. Sempowski, Barton F. Haynes
  • Polyvalent immunogen
    Publication number: 20040086506
    Abstract: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.
    Type: Application
    Filed: May 8, 2003
    Publication date: May 6, 2004
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Bette T. Korber, Robert M. De Lorimier, Hua-Xin Liao
  • Immunogen
    Publication number: 20040039172
    Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
    Type: Application
    Filed: August 25, 2003
    Publication date: February 26, 2004
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
  • Polyvalent immunogen
    Publication number: 20040001851
    Abstract: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.
    Type: Application
    Filed: February 26, 2003
    Publication date: January 1, 2004
    Inventors: Barton F. Haynes, Bette T. Korber, Robert M. De Lorimier
  • HIV envelope V3-CCR5 binding site immunogen
    Publication number: 20030219452
    Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
    Type: Application
    Filed: November 27, 2002
    Publication date: November 27, 2003
    Inventors: Barton F. Haynes, Bette T. Korber
  • Polyvalent immunogen
    Publication number: 20030147888
    Abstract: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against IV and to a polyvalent immunogen suitable for use in such a method.
    Type: Application
    Filed: November 7, 2002
    Publication date: August 7, 2003
    Inventors: Barton F. Haynes, Bette T. Korber, Robert M. De Lorimier
  • Assay system
    Patent number: 6544747
    Abstract: The present invention relates, in general, to an assay system and, in particular, to a molecular assay system for the detection and/or quantification of mouse T cell receptor excision circles. The present system can be used to detect newly produced naïve T lymphocytes and to monitor thymic output and T lymphocyte immune reconstitution in mice.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: April 8, 2003
    Assignee: Duke University
    Inventors: Barton F. Haynes, Gregory D. Sempowski, Hua-Xin Liao
  • Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens or infectious agents
    Publication number: 20030022826
    Abstract: The present invention relates, in general, to the use of synthetic peptides to induce tolerance to immunogenic peptides. In particular, the present invention relates to a method of inducing tolerance in a mammal to an immunogenic peptide or protein comprising administering to a mammal a synthetic toleragen comprising a hydrophobic peptide linked to the N-terminus or C-terminus of the immunogenic peptide or protein, under conditions such that the tolerance is induced.
    Type: Application
    Filed: September 21, 2001
    Publication date: January 30, 2003
    Applicant: DUKE UNIVERSITY
    Inventor: Barton F. Haynes
  • Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
    Patent number: 6432405
    Abstract: The present invention relates to a method of inhibiting HIV infection of cells susceptible to HIV infection. The method comprises contacting such cells with an agent (such as an anti-CD44 antibody) that inhibits CD44-facilitated HIV infection of the cells.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: August 13, 2002
    Assignee: Duke University
    Inventors: J. Brice Weinberg, Barton F. Haynes
  • Immunogen
    Publication number: 20020086283
    Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
    Type: Application
    Filed: September 24, 2001
    Publication date: July 4, 2002
    Inventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
  • Assay system
    Publication number: 20020068297
    Abstract: The present invention relates, in general, to an assay system and, in particular, to a molecular assay system for the detection and/or quantification of mouse T cell receptor excision circles. The present system can be used to detect newly produced naïve T lymphocytes and to monitor thymic output and T lymphocyte immune reconstitution in mice.
    Type: Application
    Filed: October 11, 2001
    Publication date: June 6, 2002
    Inventors: Barton F. Haynes, Gregory D. Sempowski, Hua-Xin Liao
  • Adjuvant
    Publication number: 20020052318
    Abstract: The present invention relates, in general, to an adjuvant and, in particular, to an adjuvant that induces durable systemic and mucosal humoral, Th and/or CTL responses. The invention further relates to a composition, e.g., an immunogenic composition, comprising an immunogen and the adjuvant of the invention, and to a method of enhancing an immune response to an immunogen or immunogens using such an adjuvant.
    Type: Application
    Filed: August 27, 2001
    Publication date: May 2, 2002
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Hua-Xin Liao, Dhavalkumar D. Patel
  • Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
    Publication number: 20010041180
    Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).
    Type: Application
    Filed: June 5, 2001
    Publication date: November 15, 2001
    Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
  • Human immunodeficiency virus vaccine
    Publication number: 20010036461
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.
    Type: Application
    Filed: February 5, 2001
    Publication date: November 1, 2001
    Inventors: Barton F. Haynes, Hua-Xin Liao
  • Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
    Patent number: 6270758
    Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: August 7, 2001
    Assignee: Duke University
    Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
  • SCID mouse engrafted with human synovium tissue
    Patent number: 6091000
    Abstract: The present invention relates, in general, to severe combined immunodeficiency disease (SCID) mice yand, in particular, to SCID mice engrafted with synovium and the methods of using same.
    Type: Grant
    Filed: August 20, 1992
    Date of Patent: July 18, 2000
    Assignee: Duke University
    Inventor: Barton F. Haynes
  • Anti-CD6 ligand antibodies
    Patent number: 5998172
    Abstract: The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: December 7, 1999
    Assignees: Duke University, Bristol-Myers Squibb Company
    Inventors: Barton F. Haynes, Alejandro Aruffo, Dhavalkumar D. Patel, Michael A. Bowen, Hans Marquardt, Anthony W. Siadak
  • Synthetic vaccine for protection against human immunodeficiency virus infection
    Patent number: 5993819
    Abstract: The present invention relates to immunogenic preparations of peptides comprising amino acid sequences corresponding to antigenic determinants of the envelope glycoprotein of HIV, covalently coupled, directly or through a spacer molecule, to carrier molecules suitable for vaccination of mammals.
    Type: Grant
    Filed: October 20, 1995
    Date of Patent: November 30, 1999
    Assignee: Duke University
    Inventors: Barton F. Haynes, Thomas J. Palker
  • CD6 ligand encoding sequence
    Patent number: 5968768
    Abstract: The present invention relates to an isolated nucleic acid molecule having a sequence that encodes a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to a construct containing the nucleic acid molecule and to a host cell comprising same. Further, the invention relates to a method of producing a CD6 ligand.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: October 19, 1999
    Assignees: Duke University, Bristol-Myers Squibb Company
    Inventors: Barton F. Haynes, Alejandro Aruffo, Dhavalkumar Patel, Michael A. Bowen, Hans Marquardt
  • Adhesion molecule
    Patent number: 5863540
    Abstract: The present invention relates, in general, to a method of treating inflammation or inhibiting cancer cell metastasis. In particular, the present invention relates to a method of suppressing T cell activation, inhibiting CD44-mediated cell adhesion and CD44-monocyte IL1 release, treating inflammation, and transporting a drug to a site of inflammation.
    Type: Grant
    Filed: October 29, 1993
    Date of Patent: January 26, 1999
    Assignee: Duke University
    Inventors: Barton F. Haynes, Karen L. Patton, Hua-Xin Liao